3 September 2020
The funding – which has attracted an additional $28 million in industry contributions – comes from the second and third rounds of the Biomedical Translation Bridge (BTB) program, an initiative of the Medical Research Future Fund operated by MTPConnect.
MTPConnect Managing Director and CEO, Dr Dan Grant, says round three of BTB specifically targeted COVID-19 projects (medical devices, diagnostics, prophylactic or therapeutic approaches) that will achieve an impact in less than 12-months.
“Five of the 13 projects and $4.1 million respond to the immediate priority of addressing the COVID-19 health emergency, including a vaccine candidate being developed in South Australia, a new treatment for respiratory complications of COVID-19 selected for a global WHO-endorsed clinical study, a preventive nasal spray developed from an approved antiviral, a rapid response test to predict severity of disease progression and a ventilated hood to better care for patients and protect healthcare staff,” Dr Grant said.
“Another eight selected projects and $6.3 million will help patients of the future benefit from new research into treatments and diagnostics for conditions such as muscular dystrophy, breast cancer, metabolic and fibrotic disease, prostate cancer, ataxia, antimicrobial resistance and the Zika virus.
“In two highly competitive rounds, our independent and expert evaluation committees have selected projects in South Australia, Queensland, Victoria and NSW.
“The $10.4 million we’ve allocated to these 13 projects has leveraged an additional $28 million in contributions from industry which means a total of $38.4 million is flowing into the biomedical sector.
“Through the BTB program and the MRFF we are backing promising COVID-19 related research and with an emphasis on rapid translation these projects could potentially make a real difference to patients in Australia and overseas soon.
“Building home-grown translational and commercialisation capacity means boosting our knowledge economy and creating new products, jobs and exports. This is particularly important now as we deal with the health and economic challenges of the COVID-19 pandemic and lockdown,” Dr Grant said.
The Biomedical Translation Bridge program provides up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage, operating in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.
Further details about the 13 successful projects are listed here.